Trial site
Neurology Center of North Orange County
- 15running trials
- 7closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease12 trials
- Migraine5 trials
- Mild cognitive impairment4 trials
- Parkinson disease3 trials
- Myasthenia gravis1 trial
- Stroke1 trial
- Phase
- Phase 314 trials
- Phase 26 trials
- Status
- Active, not recruiting11 trials
- Terminated4 trials
- Completed3 trials
- Recruiting3 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Hoffmann-La Roche3 trials
- Ipsen3 trials
- Biogen2 trials
- Cassava Sciences, Inc.2 trials
- Cognito Therapeutics, Inc.2 trials
- and 8 more
Running trials
Recruiting
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Recruiting
Recruiting
Active, not recruiting
Enrolling by invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease1 recruiting
- Migraine1 recruiting
- Mild cognitive impairment1 recruiting
- Myasthenia gravis1 recruiting
- Parkinson disease1 recruiting
Closed trials
Completed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
Completed
Completed
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Terminated
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Terminated
Site data: ClinicalTrials.govUpdated 18 Nov 2026